Tuberculosis Clinical Trial
Official title:
Open-label Prospective Noncomparative Study of Safety, Tolerability and Pharmacokinetics of PBTZ169 After Single and Multiple Fasting Oral Administration in Increasing Doses in Healthy Volunteers
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending dose randomized cohort study of PBTZ169 (capsules 40 mg) in fasted healthy volunteers after single and multiple oral administration
Open-label prospective non-comparative safety, tolerability and pharmacokinetics ascending
dose randomized cohort study of PBTZ169 (capsules 40 mg) in adult man healthy volunteers
after single and multiple oral fasting administration. Study was conducted in one study
center in Russian Federation. The study included two stages:
- Stage 1 - single oral fasting administration with dose escalation in 5 cohorts 6 healthy
man volunteers each in main groups (plus 1 back-up volunteer in every group);
- Stage 2 - multiple oral fasting administration with dose escalation in 2 cohorts 6
healthy man volunteers each in main groups (plus 1 back-up volunteer in every group).
Screening procedures for each cohort performed within 7 days before the drug prescription and
after the end of administration period in previous cohort. Screening in cohorts 2 and 6 was
started only after safety tolerability and PK data analysis of previous cohorts.
All volunteers met the study inclusion/exclusion criteria was included successively into the
following cohorts on Stage 1 (actual data):
- Cohort 1 (C1) - 6 volunteers of the main group each of whom received once single dose of
the drug - 1 capsule containing 40 mg of PBTZ169;
- Cohort 2 (C2) - 6 volunteers of the main group each of whom received once 80 mg of
PBTZ169 (2 capsules 40 mg);
- Cohort 3 (C3) - 6 volunteers of the main group each of whom received once 160 mg of
PBTZ169 (4 capsules 40 mg);
- Cohort 4 (C4) - 6 volunteers of the main group each of whom received once 320 mg of
PBTZ169 (8 capsules 40 mg);
- Cohort 5 (C5) - 6 volunteers of the main group each of whom received once 640 mg of
PBTZ169 (16 capsules 40 mg).
On Stage 2 (actual data):
- Cohort 6 (C6) - 5 volunteers of the main group each of whom received 320 mg of PBTZ169
(8 capsules 40 mg) once daily for 14 days;
- Cohort 7 (C7) - 5 volunteers of the main group each of whom received 640 mg of PBTZ169
(16 capsules 40 mg) once daily for 14 days.
Safety was assessed throughout the study. For every volunteer series of urine and venous
blood samples was collected for the safety, tolerability and PK assessment of PBTZ169.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05738681 -
Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial
|
Phase 2/Phase 3 | |
Recruiting |
NCT05526885 -
Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa
|
N/A | |
Completed |
NCT04369326 -
Community Initiated Preventive Therapy for TB
|
N/A | |
Recruiting |
NCT04568967 -
TB-CAPT EXULTANT - HIV
|
N/A | |
Completed |
NCT02337270 -
Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol
|
Phase 1 | |
Not yet recruiting |
NCT06253715 -
Shortened Regimen for Drug-susceptible TB in Children
|
Phase 3 | |
Recruiting |
NCT04271397 -
Immunological Biomarkers in Tuberculosis Management
|
N/A | |
Withdrawn |
NCT03639038 -
Tuberculosis Diagnosis by Flow Cytometry
|
||
Completed |
NCT03199313 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid
|
Phase 1 | |
Recruiting |
NCT04975178 -
Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa
|
Phase 3 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03973970 -
Assessing the Ability of the T-SPOT®.TB Test (IQ)
|
||
Recruiting |
NCT04230395 -
Alcohol Reduction Among People With TB and HIV in India
|
N/A | |
Completed |
NCT04874948 -
Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment
|
Phase 1 | |
Active, not recruiting |
NCT02906007 -
Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05917210 -
Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda
|
N/A | |
Not yet recruiting |
NCT06017843 -
Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding
|
N/A | |
Not yet recruiting |
NCT05845112 -
Start Taking Action For TB Diagnosis
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Completed |
NCT02781909 -
Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis
|
Phase 2 |